XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration, License and Success Payment Agreements - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Jun. 30, 2021
Apr. 30, 2021
Jul. 31, 2019
May 31, 2019
Fred Hutch Collaboration Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration agreement expense $ 1,100,000 $ 1,000,000.0   $ 3,100,000 $ 3,000,000.0          
Fair value of success payments net 21,700,000     21,700,000   $ 8,000,000.0        
Success payment expense $ (800,000) 1,200,000   $ 14,100,000 3,800,000          
Estimated fair value per share $ 1.83     $ 1.83            
Fred Hutch Collaboration Agreement [Member] | Minimum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate success payment       $ 10,000,000.0            
Share issued price per share 18.29     $ 18.29            
Fred Hutch Collaboration Agreement [Member] | Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate success payment       $ 200,000,000.0            
Share issued price per share $ 91.44     $ 91.44            
Fred Hutch Collaboration Agreement [Member] | Maximum [Member] | 50x [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate success payment       $ 200,000,000.0            
Stanford Collaboration Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration agreement expense $ 800,000 0   2,300,000 0          
Fair value of success payments net 23,100,000     23,100,000   8,900,000        
Success payment expense $ 1,000,000.0 0   $ 5,200,000 0          
Estimated fair value per share $ 1.83     $ 1.83            
Stanford Collaboration Agreement [Member] | Minimum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate success payment       $ 10,000,000.0            
Share issued price per share 18.29     $ 18.29            
Stanford Collaboration Agreement [Member] | Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate success payment       $ 200,000,000.0            
Share issued price per share $ 91.44     $ 91.44            
Stanford Collaboration Agreement [Member] | Maximum [Member] | 50x [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate success payment       $ 200,000,000.0            
GSK Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Agreement upfront consideration $ 45,000,000.0     45,000,000.0         $ 45,000,000.0  
Maximum potential future development and sales milestone payment               $ 400,000,000.0    
Maximum potential future technology validation milestone payment 200,000,000.0     200,000,000.0            
Transaction price, revenue contract       103,600,000            
Revenue recognized 2,600,000 $ 1,100,000   7,700,000 $ 5,400,000          
Additional allocated upfront consideration       58,600,000            
GSK License Contract [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Contract assets 0     0            
Contract liabilities 0     0            
Revenue recognized 0     0            
PACT Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Total upfront payment for collaboration agreement     $ 63,600,000              
License fees     $ 50,000,000.0              
Shares purchased     17,806,901              
Share price     $ 2.81              
Estimated shares purchased, fair value per share     $ 2.05              
Additional allocated upfront purchase price     $ 13,600,000              
PACT Agreement [Member] | Other Investment [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Strategic equity investment     $ 36,400,000              
G S K Already in Agreement [Member] | Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Maximum potential future development and sales milestone payment 400,000,000.0     400,000,000.0            
G S K Not Already in Agreement [Member] | Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Maximum potential future development and sales milestone payment $ 900,000,000.0     $ 900,000,000.0            
NCI License Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Agreement upfront consideration           100,000 $ 25,000      
Maintenance cost           3,100        
Total consideration           103,100        
Prespecified development milestone payment           3,100,000 $ 75,000      
Pre-specified commercial milestone payment           $ 12,000,000.0        
Series AA Convertible Preferred Stock | GSK Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Share price                   $ 6.78
Total upfront consideration                   $ 103,600,000
Shares, issued                   30,253,189
Estimated fair value per share $ 4.84     $ 4.84            
Share price $ 6.78     $ 6.78            
Additional allocated upfront consideration       $ 58,600,000